ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023. Domestic callers can join at (888) 886-7786 using confirmation number 56031524. A live webcast will also be available on ViewRay's investor relations page. The MRIdian® MR-Guided Radiation Therapy System, designed with high-definition MR imaging, addresses challenges in advanced radiation oncology, such as beam distortion and skin toxicity. This innovative technology differentiates itself from conventional MR systems used in diagnostic radiology.
Positive
- Scheduled conference call indicates proactive communication with shareholders.
- MRIdian therapy system addresses significant clinical challenges, potentially enhancing market position.
Negative
- None.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was -39.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars".
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams.
View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-preliminary-first-quarter-2023-financial-results-to-be-held-pre-market-opening-on-april-13-2023-301796074.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.